Bellicum Pharmaceuticals (NASDAQ:BLCM) Coverage Initiated at began coverage on shares of Bellicum Pharmaceuticals (NASDAQ:BLCMGet Rating) in a research report issued on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, LADENBURG THALM/SH SH lowered Bellicum Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, March 15th.

Bellicum Pharmaceuticals Price Performance

BLCM stock opened at $0.76 on Wednesday. The stock has a 50-day moving average price of $0.47 and a 200-day moving average price of $0.82. Bellicum Pharmaceuticals has a 1-year low of $0.23 and a 1-year high of $1.55.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Bellicum Pharmaceuticals stock. Susquehanna International Group LLP increased its holdings in shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCMGet Rating) by 42.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,310 shares of the biopharmaceutical company’s stock after purchasing an additional 12,616 shares during the quarter. Susquehanna International Group LLP owned approximately 0.49% of Bellicum Pharmaceuticals worth $30,000 at the end of the most recent reporting period. 28.66% of the stock is owned by institutional investors and hedge funds.

Bellicum Pharmaceuticals Company Profile

(Get Rating)

Bellicum Pharmaceuticals, Inc is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time.

Further Reading

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with's FREE daily email newsletter.